Organotypic Models for Functional Drug Testing of Human Cancers
Document Type
Article
Publication Date
6-16-2023
Publication Title
BMEF
Keywords
washington; isb
Abstract
In the era of personalized oncology, there have been accelerated efforts to develop clinically relevant platforms to test drug sensitivities of individual cancers. An ideal assay will serve as a diagnostic companion to inform the oncologist of the various treatments that are sensitive and insensitive, thus improving outcome while minimizing unnecessary toxicities and costs. To date, no such platform exists for clinical use, but promising approaches are on the horizon that take advantage of improved techniques in creating human cancer models that encompass the entire tumor microenvironment, alongside technologies for assessing and analyzing tumor response. This review summarizes a number of current strategies that make use of intact human cancer tissues as organotypic cultures in drug sensitivity testing.
Clinical Institute
Cancer
Department
Institute for Systems Biology
Department
Oncology
Recommended Citation
Huang, Yu Ling; Dickerson, Lindsay K.; Kenerson, Heidi; Jiang, Xiuyun; Pillarisetty, Venu; Tian, Qiang; Hood, Leroy; Gujral, Taranjit S.; and Yeung, Raymond S., "Organotypic Models for Functional Drug Testing of Human Cancers" (2023). Articles, Abstracts, and Reports. 7807.
https://digitalcommons.providence.org/publications/7807
